CytomX Therapeutics, Inc.

NASDAQ:CTMX

Biotechnology

Healthcare
$1.88 -0.91%

-$0.03 today

Market cap
$409.85M
Beta
2.09
P/E (TTM)
-8.8
EPS (TTM)
-$0.33
52W Low $1.72High $8.21

Volume 4.39M

Average 4.99M

Returns on capital

CytomX Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-17.5%

avg 1705.4%

ROIC

-20.5%

avg -22.7%

ROA

-11.5%

avg -16.6%

Analysis

ROA is currently the strongest return metric at -11.5% versus its period average of -16.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Sean A. McCarthy DPHIL

Chairman & Chief Executive OfficerUSD 1.43M59——

Christopher W. Ogden

SVP, CFO & SecretaryUSD 871.33K42——

Marcia Belvin

Senior Vice President & Chief Scientific OfficerUSD 634.83K59300.76K0.19%

Yu-Waye Chu

Senior VP & Chief Medical OfficerUSD 496.94K58189.45K0.12%

Rachael Lester

Chief Business Officer & Senior Vice PresidentUSD 241.52K4820.00K0.01%

Stephanie Robertson

Senior Vice President of Alliances & Program Leadership————

Alejandra Veronica Carvajal

Chief Legal Officer—52——

Danielle Olander-Moghadassian

Senior Vice President & Chief Human Resources Officer————

Dawn Benson

Senior Vice President of Quality & Product Manufacturing————

Leslie Robbins

Senior Vice President of Intellectual Property————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 17, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

5

$1.23M

Net Transaction Value

−$1.23M

Net selling

Most Active

Ogden Christopher

2 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jun 15, 26

Ogden Christopher

Direct

Sell$5K
Mar 17, 26

Chu Yu-Waye

Direct

Sell$136.7K
Mar 17, 26

McCarthy Sean A.

Direct

Sell$764.1K
Mar 17, 26

BELVIN MARCIA

Direct

Sell$202.3K
Mar 17, 26

Ogden Christopher

Direct

Sell$124.1K

Summary

Insiders reported 0 buys worth $0.00 and 5 sells worth $1.23M over the last 12 months. That adds up to net selling of $1.23M. Ogden Christopher was the most active insider with 2 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+12.8%
+21.3% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at +12.8% over three years. Forward estimates point to Revenue at +21.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does CytomX Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CTMX's management, answered from reported figures.

Who manages CTMX?

CytomX Therapeutics, Inc. (CTMX) lists 10 active executives. The top listed executive is Marcia Belvin, Senior Vice President & Chief Scientific Officer.

Are CTMX insiders buying or selling?

Recent insider activity shows net buying of $24.34M.